2015
An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate
Gueorguieva R, Wu R, Tsai WM, O’Connor P, Fucito L, Zhang H, O’Malley S. An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. European Neuropsychopharmacology 2015, 25: 1586-1599. PMID: 26141511, PMCID: PMC4600651, DOI: 10.1016/j.euroneuro.2015.06.006.Peer-Reviewed Original ResearchConceptsAcamprosate effectHeavy drinkingShort abstinenceEnhanced treatment responseMonths of treatmentSubgroup of patientsBody mass indexDrug plasma levelsIdentification of subgroupsBetter prognosisLower BMIMass indexPlasma levelsGlutamatergic hyperactivityTreatment responseAcamprosateCOMBINE StudyPrior treatmentLarger studyConsecutive daysAbstinencePretreatment abstinenceTreatment effectsCognitive inefficiencySubgroups
1997
A Preliminary Investigation of the Management of Alcohol Dependence With Naltrexone by Primary Care Providers
O’Connor P, Farren C, Rounsaville B, O’Malley S. A Preliminary Investigation of the Management of Alcohol Dependence With Naltrexone by Primary Care Providers. The American Journal Of Medicine 1997, 103: 477-482. PMID: 9428830, DOI: 10.1016/s0002-9343(97)00271-4.Peer-Reviewed Original ResearchConceptsPrimary care providersCare providersGamma-glutamyl transferaseAlcohol dependenceDays abstinentHeavy drinkingSerum gamma-glutamyl transferaseCare treatment modelCompletion of treatmentPercent days abstinentAlcohol-dependent subjectsAlcohol-dependent individualsNaltrexone therapyNumber of drinksPrimary outcomeLiver enzymesPatient ratingsNew patientsGlutamyl transferaseNaltrexoneProvider ratingsBaselineTreatment modelTreatmentDrinking behavior